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Abstract
Drug resistant HIV is a major threat to the long-term efficacy of antiretroviral treatment.
Around 10% of ART-naïve patients in Europe are infected with drug-resistant HIV type 1.
Hence it is important to understand the dynamics of transmitted drug resistance evolution.
Thanks to routinely performed drug resistance tests, HIV sequence data is increasingly
available and can be used to reconstruct the phylogenetic relationship among viral lineages.
In this study we employ a phylodynamic approach to quantify the fitness costs of major
resistance mutations in the Swiss HIV cohort. The viral phylogeny reflects the transmission
tree, which we model using stochastic birth–death-sampling processes with two types:
hosts infected by a sensitive or resistant strain. This allows quantification of fitness cost as
the ratio between transmission rates of hosts infected by drug resistant strains and transmis-
sion rates of hosts infected by drug sensitive strains. The resistance mutations 41L, 67N,
70R, 184V, 210W, 215D, 215S and 219Q (nRTI-related) and 103N, 108I, 138A, 181C,
190A (NNRTI-related) in the reverse trancriptase and the 90M mutation in the protease
gene are included in this study. Among the considered resistance mutations, only the 90M
mutation in the protease gene was found to have significantly higher fitness than the drug
sensitive strains. The following mutations associated with resistance to reverse transcrip-
tase inhibitors were found to be less fit than the sensitive strains: 67N, 70R, 184V, 219Q.
The highest posterior density intervals of the transmission ratios for the remaining resis-
tance mutations included in this study all included 1, suggesting that these mutations do not
have a significant effect on viral transmissibility within the Swiss HIV cohort. These patterns
are consistent with alternative measures of the fitness cost of resistance mutations. Overall,
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we have developed and validated a novel phylodynamic approach to estimate the transmis-
sion fitness cost of drug resistance mutations.
Author summary
The introduction of antiretroviral therapy (ART) has decreased mortality and morbidity
rates among HIV-infected people, and improved their quality of life. In fact, the WHO
states that antiretroviral therapy programmes averted an estimated 7.8 million deaths
worldwide between 2000 and 2014. However, the antiretroviral regimen prescribed to a
patient may be unable to control HIV infection. Factors that can contribute to treatment
failure include drug resistance, drug toxicity, or poor treatment adherence. In this study
we aim to understand the dynamics of transmitted drug resistance by analysing the viral
sequence data that was collected for resistance testing. We present a novel approach to
quantify how drug resistance impacts virus lineage transmissibility, how fast resistance
mutations evolve in sensitive strains and how fast they revert back to the sensitive type.
We apply our approach to the Swiss HIV cohort study, and obtain patterns of viral trans-
mission fitness that are consistent with alternative, harder to obtain measures of fitness.
Introduction
The emergence and subsequent spread of drug resistant human immunodeficiency virus type
1 (HIV-1) is a major threat to the long-term efficacy of antiretroviral treatment. Around 10%
of antiretroviral therapy (ART)-naïve patients in Europe are infected with drug-resistant HIV-
1 and transmitted drug resistance (TDR) has been associated with a higher virological failure
rate during treatment [1–9]. The dynamics of TDR depend largely on the respective resistance
mutation and requires quantification of their fitness cost. Estimates of fitness costs, resistance
evolution and reversion rates could previously only be obtained by comparing the replication
kinetics of the virus after infection of cell cultures or more complicated experimental tech-
niques [10] or through longitudinal cohort studies [11, 12]. These methods are essential in
understanding the type of fitness cost related to replication within the host. Here we are inter-
ested in a different type of viral fitness, namely the transmission fitness, which describes the
success of a viral lineage in transmission between hosts.
As pol sequences are routinely collected from infected individuals to test for drug resistance,
HIV sequence data is increasingly available. These sequences can be used to reconstruct the
phylogenetic relationship among viral lineages, which is an approximation of the transmission
tree. A considerable number of phylogenetic and phylodynamic approaches for the analysis of
pathogen outbreaks have been developed in the last decade and have greatly contributed to a
better understanding of the dynamics of HIV epidemics [13–19].
In this study we employ a phylodynamic approach to quantify the fitness costs of major
resistance mutations using data from the Swiss HIV cohort study (SHCS) and the associated
drug resistance database. Our approach is based on stochastic birth–death–sampling pro-
cesses, which have been shown to be suitable for the modelling of epidemic processes [20]. In
terms of the transmission tree a “birth” event corresponds to the infection of a new host, a
“death” event corresponds to the host’s removal from the infectious pool (e.g. successful treat-
ment). The removed host may or may not have been sampled before removal, which corre-
sponds to the viral strain being sequenced and included in the SHCS.
Phylodynamic quantification of HIV-1 drug resistance fitness cost
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We consider each major resistance mutation separately such that our model requires
exactly two types, sensitive and resistant, between which we assume a simple ‘migration’ pro-
cess of resistance evolution and reversion, see Fig 1.
The aim of this paper is to demonstrate that our phylodynamic approach can shed light on
the dynamics of HIV resistance evolution. In fact, the approach we present here allows us to
quantify the fitness cost of major resistance mutations (i.e. λr/λs in Fig 1), as well as the rates
at which resistance mutations evolve and are reversed, on a population level. Notably, our
approach requires only cross-sectional viral sequence data annotated with dates of sampling.
Materials and methods
SHCS sequence data set
The SHCS is a multicentre, prospective observational study for interdisciplinary human
immunodeficiency virus (HIV) research, with an estimated coverage of more than 45% of all
HIV cases in Switzerland overall and more than 70% since 1996 [21].
The associated drug resistance database is a central, anonymised collection of all genotypic
drug resistance tests performed on SHCS enrolees. The base data set used in this study con-
tains the first HIV-positive (subtype B) samples of treatment naïve SHCS patients. Due to the
availability of the SHCS biobank, in total more than 12000 genotypes could be generated retro-
spectively, making the SHCS one of the globally most densely sampled populations [6]. In par-
ticular, all patients with available samples present before the start of ART were retrospectively
Fig 1. The two-type birth–death model with types ‘sensitive’ and ‘resistant’. Virus samples are grouped into the
compartments by their resistance status (corresponding to a single major resistance mutation). Transmission at
transmission rates λs and λr can only occur within the sensitive and resistant compartment, respectively. In either
compartment, removal from the infectious pool occurs at rate δ. The compartments are connected by (exponential)
rates of resistance evolution and reversion.
https://doi.org/10.1371/journal.ppat.1006895.g001
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sequenced. This is of particular importance because in general, HIV drug resistance testing
was not routinely performed before 2003 in Switzerland or even later in other countries.
Hence, the sampling dates of the sequences included here range from as early as 1989 to 2015.
The resulting 5638 pol sequences were combined with the 4284 most closely related
sequences selected from the LANL database using BLAST (allowing up to 10 hits per sequence;
expect value = 1 × 10−30). The resulting 9922 sequences were aligned against the HBX2 subtype
B reference strain and the alignment was stripped off the major resistance mutations listed by
the IAS-USA [22]. A maximum likelihood phylogeny of the alignment was reconstructed in
FastTree version 2.1.9 [23] assuming a GTR model of molecular evolution with gamma distrib-
uted rate heterogeneity. The resulting phylogeny was used to identify all sub-epidemics with at
least two samples for which a minimum of 80 per cent of the samples were from Switzerland
[14]. In the following we refer to these Swiss sub-epidemics as clusters. For computational rea-
sons any cluster that contained more than 250 sequences was split at the root of the phylogeny
and considered as two separate clusters.
For each of the major resistance mutations we selected all clusters that contained at least
one sequence in which the respective mutation was present. From the remaining samples that
did not have the respective mutation, we removed sequences in which any of the other major
resistance mutations were present ( 10%). Hence, the sequences in the resulting clusters are
either ‘truly sensitive’, or contain the respective resistance mutation. From the resulting resis-
tance mutation related data sets (RMDS) we included only those that met the following two
criteria: Summing over all clusters (i) the total number of sequences is 25 and (ii) the num-
ber of resistant sequences is 10 (see Table 1). Numbers of resistant and total samples per
RMDS per cluster are illustrated in S1 Fig. More detailed cluster characteristics are given in
Table 3 within S1 Text. Exemplary analysis files are provided in S1 File.
Phylodynamic analyses
The 15 RMDS were analysed using the multi-type birth–death model [18] in BEAST2 [24]. A
single analysis was set up for each of the resistance mutations. The sequences were annotated
with their date of sampling and type (sensitive or resistant) and the phylogenies for each
Table 1. Resistance mutations with numbers of corresponding clusters and samples, related drugs and drug usage dates within Switzerland.
nRTI NNRTI PI
Resistance mutation 41L 67N 70R 184V 210W 215D 215S 215Y 219Q 103N 108I 138A 181C 190A 90M
Number (#) of clusters of size 2 56 23 19 35 18 18 16 25 20 25 10 46 8 8 14
# Sequences in clusters 927 667 712 1011 481 569 494 807 605 725 334 1014 329 311 389
# Resistant samples in clusters 93 39 26 44 26 41 31 28 28 38 11 109 10 12 38
Drug
(SHCS drug codes)
AZT
D4T
AZT
D4T
AZT
D4T
3TC
ABC
FTC
AZT
D4T
AZT
D4T
AZT
D4T
AZT
D4T
AZT
D4T
NVP
EFV
NVP
EFV
RPV NVP
EFV
ETV
RPV
NVP
EFV
NFV
SQV
Drug usage 1% 1987 1987 1987 1995.5 1987 1987 1987 1987 1987 1997 1997 2013 1997 1997 1996
Drug usage < 1% - - - - - - - - - - - - - - 2008
nRTIs: Resistance mutation related to nucleoside/nucleotide reverse transcriptase inhibitors
NNRTIs: Resistance mutation related to non-nucleoside reverse-transcriptase inhibitors
PIs: Resistance mutation related to protease inhibitors
‘Drug usage 1%’ refers to the time at which the respective drug was prescribed to a minimum of one percent of patients within the SHCS. If multiple drugs are
associated with a resistance mutation the earliest date is used. Accordingly, ‘Drug usage < 1%’ refers to the time when the respective drugs are no longer used in 1% of
the patients.
https://doi.org/10.1371/journal.ppat.1006895.t001
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cluster were reconstructed jointly with the epidemiological parameters. While the tree topol-
ogy, tree height and length, the branch rate variation and sampled ancestors [25] were esti-
mated separately for each of the clusters, the substitution rate and epidemiological parameters
were estimated jointly for all clusters. The parameters that were estimated jointly for all clus-
ters associated with a particular resistance mutation were informed by the phylogenies of these
clusters together. For example, we estimate a single resistance evolution rate for each resistance
mutation, such that all clusters contribute to the estimate of the resistance evolution rate. The
unit of time used in our analyses is years, such that all rates estimated here are average rates
per lineage per year.
Fig 1 depicts the two-type birth–death model employed. Transmission events can only
occur within each type, i.e. a transmission event caused by a sensitive strain results in a new
infection with a sensitive strain and likewise for resistant strains. The migration rates estimated
from sensitive to resistant lineages and back are equivalent to population-level rates of resis-
tance evolution and reversion, respectively. Specifically, moving from the sensitive compart-
ment to the resistant compartment is modelled through a resistance evolution rate, the
opposite direction is determined by the resistance reversion rate. Both rates are assumed to be
zero before significant usage of the related drug(s) in Switzerland. We consider drug usage as
significant whenever the respective drug is prescribed to a minimum of one percent of patients
within the SHCS. The NNRTI-related mutation 138A is an exception because it occurred in
0.5% to 5% of viruses from treatment-naïve patients even before the introduction of the related
drug rilpivirine [26, 27]. Hence, we do not assume the resistance evolution and reversion rates
for the 138A mutation to be zero at any time. Instead we allow the rate to change in 2013,
when usage of the respective drug in Switzerland became significant. The protease inhibitors
related to resistance mutation 90M have been used in less than 1% of patients after 2008.
Therefore, we allow the resistance evolution and reversion rates for the 90M mutation to
change in a piecewise constant fashion, such that it is zero before 1996 and we obtain one esti-
mate for the time during and one for after significant drug usage in Switzerland.
The effective reproduction number of the sensitive type through time, which is the quotient
of the sensitive transmission rate over the removal rate: Rs = λs/δ, is allowed to change over
seven-year intervals (before 1994, 1994-2001, 2001-2008, 2008-2015) in a piecewise constant
fashion. We estimate a constant between-host transmission ratio
rl ¼
lr
ls
between the per lineage resistant transmission rate λr and the sensitive transmission rate λs.
Hence, rλ< 1 implies that there is a fitness cost associated with a resistance mutation. On the
other hand rλ> 1 suggests that the resistance mutation confers an advantage to the viral strain.
We assume a joint removal rate δ for both types.
The analyses were conducted using a HKY substitution model with gamma distributed rate
heterogeneity and a relaxed clock model with lognormally distributed branch rates. The substi-
tution rate was fixed to 2.55  10−3 [28]. For each cluster sampling was assumed to have started
at the sampling time of its earliest sequence. We estimate a constant sampling proportion p
with its prior distribution centered around 22%, which results from considering that about
50% of the HIV infected population in Switzerland is included in the SHCS, 67% of which
have successfully been sequenced [21] and 65% of which are treatment naïve. Upon sampling,
individuals are removed from the infectious pool at a removal probability r. This means that
we allow sampled ancestors [25] in the reconstructed phylogenies implying that infected
Phylodynamic quantification of HIV-1 drug resistance fitness cost
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individuals may still transmit to others after they have been diagnosed. The prior distributions
employed are listed in Table 2.
Multiple independent instances were run for each RMDS, which were then combined,
resulting in a combined Markov chain length of at least 250 million after burn-in. The resulting
effective sample size of each parameter estimated is greater or equal to 200. This unusually long
chain length was necessary due to the setup of the analyses: In each analysis we reconstruct the
phylogenies for 8 to 56 clusters, many of which are very small (down to 2 samples), but some of
which are fairly large (up to 184 samples), which makes operator optimisation difficult.
Ethics statement
The SHCS was approved by the ethics committees of the participating institutions (Kantonale
Ethikkommission Bern, Ethikkommission des Kantons St. Gallen, Comite Departemental
d’Ethique des Specialites Medicales et de Medicine Communataire et de Premier Recours,
Kantonale Ethikkommission Zurich, Repubblica e Cantone Ticino—Comitato Ethico Canto-
nale, Commission Cantonale d’E´tique de la Recherche sur l’Eˆtre Humain, Ethikkommission
beider Basel; all approvals are available on http://www.shcs.ch/206-ethic-committee-approval-
and-informed-consent), and written informed consent was obtained from all participants.
Results
After applying the selection criteria described in the Methods section, we obtained 15 RMDS
with 8 (181C & 190A) to 56 (41L) clusters per resistance mutation comprising a total of 311
(190A) to 1014 (138A) sequences (Table 1). The total number of patients included in the study
after applying the above criteria is 2614. Most clusters contain very few resistant samples. Sen-
sitive samples are allowed to occur in multiple RMDS. Histograms of the numbers of (i) all
and (ii) resistant samples per cluster are shown in S1 Fig. As an example of the resulting recon-
structed cluster phylogenies, Fig 2 shows the maximum clade credibility trees of one cluster
per drug class.
We were unable to obtain reliable estimates for the 215Y RMDS, as the MCMC did not con-
verge even after more than 2.400 million combined MCMC steps (for details see Section 3.1
within S1 Text). Hence we present the results from the remaining 14 RMDS only.
We quantify the transmission dynamics of the drug sensitive virus samples by estimating
the effective reproduction number, Rs, through time. This yields one estimate for each of the
14 RMDS, which agree with one another (depicted by 14 overlapping violin plots per time
interval, Fig 3). Our results suggest that Rs was above 2 before 1994, below the epidemic thresh-
old of one between 1994 and 2001 and around 1 after 2001.
For each resistance mutation we quantify the between-host fitness cost as the ratio rλ of the
transmission rate of the drug resistant strains divided by the transmission rate of the drug sen-
sitive strain. Among the considered resistance mutations, only the 90M mutation in the prote-
ase gene was found to have significantly higher fitness than the drug sensitive strains (Fig 4).
The following mutations associated with resistance to reverse transcriptase inhibitors were
found to be less fit than the sensitive strains: 67N, 70R, 184V, 219Q. The highest posterior den-
sity intervals of the transmission ratios for the remaining resistance mutations (41L, 103N,
Table 2. Prior distributions for the birth–death model parameters.
Rs δ rλ p resistance evolution rate resistance reversion rate removal probability
LogN(0,1.25) LogN(-1,0.5) LogN(0,0.5) Beta(22,78) Exp(1) Exp(1) Unif(0,1)
https://doi.org/10.1371/journal.ppat.1006895.t002
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Fig 2. Maximum clade credibility trees of one cluster per drug class. Summary of the posterior distribution of the
reconstructed phylogeny for one exemplary cluster in the 219Q, 138A, 184V, 103N and 90M RMDS. Exemplarily, the 103N
cluster contains five resistant and seven sensitive samples. It has one sampled ancestor (indicated by the resistant sample with
zero branch length), indicating that the respective patient transmitted to at least one other person after having been diagnosed
with HIV.
https://doi.org/10.1371/journal.ppat.1006895.g002
Phylodynamic quantification of HIV-1 drug resistance fitness cost
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108I, 138A, 181C, 190A, 210W, 215D, 215S) all included the threshold one, suggesting that
these mutations do not have a significant effect on viral transmissibility within the Swiss HIV
Cohort Study.
The estimated rates of resistance evolution and reversion are shown in S2 and S3 Figs,
respectively. The median rates of resistance evolution during significant drug usage in Switzer-
land are between 0.005–0.13. The corresponding median rates of resistance reversion range
from 0.03–0.20. In detail, the posterior estimates of the epidemiological parameter estimates
are given in Table 4 within S1 Text.
Our results suggest that once the patient samples are taken, the patients are unlikely to con-
tinue transmitting to others. In fact, the median number of sampled ancestors for most RMDS
clusters is zero. Very few clusters belonging to the 215D, 108I, 181C and 190A data sets have
significantly more than zero sampled ancestors. Overall, the probability of being removed
from the infectious pool upon sampling is above 89% (smallest median estimate) for patients
infected with sensitive strains. There is much uncertainty in the estimates of the removal prob-
ability for resistant strains, which range from 44% (215D; 95% HPD: 0.7-84%) to 95% (138A;
95% HPD: 81-100%),
Discussion
In this study we present a computational method to quantify the transmission cost of HIV-1
drug resistance mutations and assess it in the context of the Swiss HIV Cohort Study, as the
Fig 3. Estimates of the effective reproduction number Rs of the sensitive strains through time. Time has been partitioned into 4 fixed time intervals: before 1994,
1994-2001, 2001-2008, 2008-2015. For each time interval there are 14 estimates, one from each of the 14 resistance-mutation data sets (RMDS). The violin plots show
the 95% HPDs of the Rs estimates.
https://doi.org/10.1371/journal.ppat.1006895.g003
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transmission of drug resistant strains is a big threat to the success of global HIV-containment
programs (e.g. test-and-treat) [29]. The base data set used here is intentionally limited to sam-
ples from patients that have not undergone antiretroviral therapy (ART) at the time of sam-
pling. Including ART experienced individuals would be problematic, because the transmission
rates estimated from ART-naïve vs. ART-experienced individuals are likely confounded by
several factors such as behavioural differences due to awareness of HIV status and the effect of
ART on viral load and persistence of drug resistance mutations [30–36].
Furthermore, we exclude resistance mutations that occur in very few samples, to avoid
identifiability issues in our analyses. Our study includes eight major resistance mutations
related to nucleoside reverse transcriptase inhibitors, five related to non-nucleoside reverse
transcriptase inhibitors and one related to protease inhibitors.
Our selection criteria serve as a filter for those drug resistance mutations that are moder-
ately prevalent and transmissible in Switzerland. Hence, they represent the most important
drug resistance mutations to be considered in Switzerland from a clinical and public health
perspective. However, this does not include very recently introduced drugs, as they may not
cross our thresholds yet. More specifically, it is unlikely to have samples from ten or more
patients with a specific mutation conferring resistance to a drug that was introduced less than
two or three years ago. For our data set this would translate to any introductions after 2013.
Our approach is based on the assumption that a viral strain can be annotated with either of
two types, sensitive or resistant. This is a strong simplification since the presence of multiple
Fig 4. Estimates of the transmission ratio of the resistant strains during consumption in Switzerland. For each resistance mutation we estimate a between-host
transmission ratio rλ = λr/λs between the per lineage resistant transmission rate λr and the sensitive transmission rate λs. The respective drug consumption dates are
given in Table 1. The violin plots show the 95% HPD intervals of the rλ estimates. The same prior distribution was employed for all analyses (plotted on the far right).
https://doi.org/10.1371/journal.ppat.1006895.g004
Phylodynamic quantification of HIV-1 drug resistance fitness cost
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drug resistance mutations may impact viral fitness in a different way than a single mutation.
However, most transmitted virus strains in this study contain either zero or one major resis-
tance mutation. We did not include compensatory mutations in our analyses due to their rare
occurrence in the data set. Furthermore, we do not distinguish among different risk groups in
this study, as there does not appear to be any significant difference in TDR prevalence accord-
ing to risk groups [37].
We are assuming that the transmission tree coincides with the phylogeny, which is based
on assuming that there is little or no superinfection and that within-host coalescence time is
short compared to the viral transmission time. In addition, we assume a constant between-
host transmission ratio rλ = λr/λs, which implies that transmission rate changes due to a
changing number of susceptible individuals or a change in public health interventions have
the same effect on sensitive and resistant hosts. This effect cancels out in the ratio. Note
that between-host transmission fitness and within-host replication fitness are intertwined.
Within-host replication fitness is one of the factors that contributes to the overall epidemio-
logical fitness of a viral strain, which is commonly measured by the effective reproduction
number [38].
There are two technical assumptions of the phylodynamic model that were made for
computational reasons only: (1) the removal rate is constant through time and (2) resistance
evolution rates can be averaged over (i) connected time periods of no or very little drug usage
(< 1%) and (ii) connected time periods of relevant usage (> 1%), see Fig 1 within S1 Text (sce-
nario A). For three of the RMDS (184V, 103N and 90M) we have performed the same analysis
again with these assumptions relaxed to have changes in removal rates at two time points and
direct dependance of the resistance evolution rates on the annual drug usage data in the SHCS
(scenario B). While we see a small decrease in the estimated transmission ratios, the 95%
HPDs largely overlap, resulting in qualitatively equivalent interpretations (see Section 1 within
S1 Text, esp. Fig 3 within S1 Text). Additionally we have conducted a simulation study in
which we simulate three sets of RMDS representative of the actual RMDS 184V, 103N and
90M under the more complex scenario B and reconstruct the trees and epidemiological
parameters under the simpler scenario A. Although this does introduce some bias into our
estimates we can robustly estimate the transmission ratio in all three simulation sets (see Sec-
tion 2 within S1 Text, esp. Fig 5 within S1 Text). In particular, the simulation study presented
in S1 Text shows that we can differentiate among different types of between-host transmission
fitness despite differences in population sizes.
While there may be variation among individuals that confounds the potential effects of
drug resistance mutations on transmission fitness, the overall patterns of viral fitness identified
in this study are consistent with other measures of the fitness cost of resistance mutations such
as site-directed mutagenesis or reversion rates [10–12]. Furthermore, Wertheim et al. [39]
have recently applied a network approach to a large data set from the United States, obtaining
results consistent with those presented here.
The 90M mutation in the protease and the 138A mutation in the reverse transcriptase have
both previously been associated with TDR even in the absence of drugs [40, 41]. In this study,
they are the only resistance mutations that have as many as ten resistant samples per cluster. In
fact, the 138A mutation occurs in the SHCS as early as 1995 although the drug (rilpivirine) was
only introduced in Switzerland in 2013. It appears to be a natural polymorphism, which is
present in 0.5% to 5% of viruses from treatment-naïve patients, although it is more common
in subtype C than B [26, 27, 40]. Before 2013 the median resistance evolution and reversion
rates are 0.008 (95% HPD: [0.005-0.01]) and 0.04 (95% HPD: [0.008-0.08]), respectively. There
is much uncertainty in the resistance evolution rate (median 0.14, 95% HPD: [0.00009-0.43])
and reversion rate (median 0.20, 95% HPD: [0.0004-0.82]) after 2013, which is due to the
Phylodynamic quantification of HIV-1 drug resistance fitness cost
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interval 2013–2015 being relatively short. We estimate a transmission ratio of 1.09 (median;
95% HPD: [0.88, 1.34]) confirming that its fitness is similar to that of sensitive strains.
The 90M mutation in the protease is another case of treatment-independent transmission
[42, 43]. Our results suggest that it confers a significant fitness advantage over the sensitive lin-
eages. While prescription of the drugs (saquinavir and nelfinavir) against which 90M confers
resistance has ceased in Switzerland around 2008, the mutation still occurs in later samples.
The latest sample showing the 90M mutation within a cluster was obtained in 2011. There are
four 90M clusters that contain more than one resistant sample, three of which are driven by
men having sex with men (MSM) and one that contains five resistant samples all of which are
from heterosexual individuals falling together in a five-sample sub-cluster. Since this appears
to reflect the situation in the Swiss HIV epidemic well [44], there does not appear to be a con-
founding effect due to risk group.
Note that these results are based on a relatively small sample size (Table 3 within S1 Text).
However, others have also estimated a fitness advantage for the 90M mutation based on an
independent data set [39]. Furthermore, it has been shown previously that 90M prevalence
increased in the Swiss HIV cohort in recent years, although it’s occurrence in patients failing
treatment is declining [6]. These studies thus support that the 90M mutation has either a fit-
ness advantage or at least no significant fitness cost.
In contrast, the 184V mutation in the reverse transcriptase stands out as the one with the
highest transmission cost (median transmission ratio: 0.43, 95% HPD: [0.18-0.66]). Being a
major nRTI mutation the 184V is the only resistance mutation in this study that has no cluster
with more than two resistant samples (apart from the 215Y RMDS for which we were not able
to obtain reliable results, see Section 3.1 within S1 Text). Hence, it appears that while the 184V
mutation evolves frequently under failing treatment, its high between-host transmission cost
results in very short transmission chains.
For the 103N mutation in the reverse transcriptase we estimate a transmission ratio of 0.97
(95% HPD, [0.57-1.41]), which may imply that the mutation confers no significant fitness
advantage or disadvantage. This major NNRTI mutation is associated with failure of current
first-line treatment [2, 9, 45, 46] and currently is the most important NNRTI [47]. The lack of
a disadvantage in transmission underlines the clinical importance of the 103N mutation in the
context of TDR, particularly in resource limited settings.
For the remaining NNRTI mutations (108I, 181C and 190A) we obtain results very similar
to the 103N results, although with larger 95% HPD intervals, particularly for the 108I RMDS,
due to small sample sizes (10-12 resistant samples per RMDS).
Extensive propagation of the 103N and 90M mutations is unlikely in Switzerland and
other resource-rich countries, where drug resistance testing is performed routinely to iden-
tify active drugs. Nevertheless, even in these settings it is crucial to diagnose HIV-positive
individuals early to decrease the prevalence of transmitted drug resistance. The transmission
potential of these mutations must be taken into account in the management of low-resource
HIV-epidemics. Although the prevalence of transmitted drug resistance appears to be lower
in African countries, for example, this may be due to the later introduction and roll-out of
ART. Hence, there is a large risk of NNRTI-resistant viruses spreading quickly in such set-
tings, which would make the management of the HIV-epidemics in resource-limited settings
very difficult.
Our results regarding sampled ancestors and the removal probability suggest that patients
infected with sensitive strains may be less likely to transmit after diagnosis than patients
infected with resistant strains. However, there is considerable uncertainty in the removal prob-
ability estimates for resistant strains. This may be overcome by including all type B samples of
the cohort (rather than only the treatment naïve first samples), which will be the subject of
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future work. In data sets where transmission frequently occurs after diagnosis and treatment,
it would be advisable to include ART status into the analysis.
The merits of molecular epidemiological approaches have been highlighted in previous
studies, particularly for cases in which genetic data is combined with epidemiological, demo-
graphic and clinical data [19, 41, 48–52]. However, this is one of the first studies presenting a
phylogenetic approach that allows direct quantification of population-level fitness costs of
HIV resistance mutations from viral sequence data (annotated with sampling date and resis-
tance type) alone. Hence, this approach may become particularly useful in assessing the risk
of TDR in resource limited settings where resistance testing is possible but epidemiological,
demographic and clinical data are missing. Furthermore, our approach is not only applicable
to HIV but to any measurably evolving pathogen.
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